LivaNova PLC (LIVN) LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC (NASDAQ: LIVN) FY 2026 Other Release
12 articles, transcripts, and reports
LivaNova PLC (NASDAQ: LIVN) FY 2026 Other Release
LivaNova PLC (NASDAQ: LIVN) Q4 2025 Earnings Call dated Feb. 25, 2026 Corporate Participants: Briana Gotlin — Vice President, Investor...
LivaNova PLC (NASDAQ: LIVN) Q4 2025 Earnings Conference
LivaNova PLC (NASDAQ: LIVN) Q4 2025 Earnings Release
LivaNova PLC (NASDAQ: LIVN) FY 2026 Other Release
LivaNova PLC (NASDAQ: LIVN) Q2 2025 Earnings Call dated Aug. 06, 2025 Corporate Participants: Briana Gotlin — Vice President, Investor Relations Vladimir Makatsaria — Chief…
LivaNova PLC (NASDAQ: LIVN) Q3 2025 Earnings Call dated Nov. 05, 2025 Corporate Participants: Briana Gotlin — Vice President, Investor Relations Vladimir Makatsaria — Chief…
LivaNova PLC (NASDAQ: LIVN) Q3 2022 Earnings Conference
LivaNova PLC (NASDAQ: LIVN) Q2 2022 Earnings Conference
LivaNova PLC (NASDAQ: LIVN) Q1 2022 Earnings Conference